Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05802329 · ClinicalTrials.gov registry record · Phase 1
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
A Phase 1 study of Diabetic Macular Edema and Center Involved Diabetic Macular Edema, sponsored by Ocugen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 5
- Study locations
NCT05802329 is a Phase 1 study of Diabetic Macular Edema and Center Involved Diabetic Macular Edema that is actively recruiting participants, run by Ocugen. The registered enrollment target is 24 participants, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT05802329, a Phase 1 study of Diabetic Macular Edema and Center Involved Diabetic Macular Edema, is actively recruiting participants, sponsored by Ocugen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 5
- Study locations
Study Summary
A Phase 1 study to assess the safety and efficacy of OCU200 for center-involved diabetic macular edema
Conditions Studied
Interventions
- DRUG OCU200
Study Locations (5)
Texas
- Retina Consultants of Texas Research Centers - Bellaire
- Retina Consultants of America - Southlake
Florida
- Advanced Research LLC - Deerfield Beach
Pennsylvania
- Erie Retina Research, LLC - Erie
Wisconsin
- Gundersen Health System - La Crosse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-01-13 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05802329
The ClinicalTrials.gov registry entry for NCT05802329 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The listed sponsor is Ocugen, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetic Macular Edema appearing as the primary indexed condition, and to 1 intervention - of which OCU200 is the first listed.
NCT05802329 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, Florida, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05802329 about?
NCT05802329 is a clinical study titled "Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)". A Phase 1 study to assess the safety and efficacy of OCU200 for center-involved diabetic macular edema
What is the current status of trial NCT05802329?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-01-13. Estimated completion is 2026-07-31.
What conditions does trial NCT05802329 study?
This clinical trial studies the following conditions: Diabetic Macular Edema, Center Involved Diabetic Macular Edema.
What interventions are being tested in trial NCT05802329?
The interventions under investigation include: OCU200 (DRUG).
Who is sponsoring clinical trial NCT05802329?
This trial is sponsored by Ocugen, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05802329 being conducted?
This trial has 5 study locations across Florida, Pennsylvania, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
RECRUITING · Phase 1
-
Kamuvudine-9 (K9) in Diabetic Macular Edema
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.